BS_BSV07M7Z
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- age_years
- 4.603
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.595
- G2M_CHECKPOINT+0.498
- DNA_REPAIR+0.458
- MYC_TARGETS_V1+0.455
- MYC_TARGETS_V2+0.326
- OXIDATIVE_PHOSPHORYLATION+0.253
- MITOTIC_SPINDLE+0.239
- SPERMATOGENESIS+0.235
- UNFOLDED_PROTEIN_RESPONSE+0.086
- PI3K_AKT_MTOR_SIGNALING+0.034
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.664
- INTERFERON_GAMMA_RESPONSE-0.624
- INFLAMMATORY_RESPONSE-0.619
- TNFA_SIGNALING_VIA_NFKB-0.603
- IL6_JAK_STAT3_SIGNALING-0.598
- ALLOGRAFT_REJECTION-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.521
- IL2_STAT5_SIGNALING-0.518
- COMPLEMENT-0.477
- KRAS_SIGNALING_UP-0.457
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_Y8D1F5WW | medulloblastoma | — | 0.989 |
| 2 | BS_G00FHF3Q | medulloblastoma | — | 0.985 |
| 3 | BS_EFE4YEK3 | medulloblastoma | — | 0.976 |
| 4 | BS_GE2RVZE6 | medulloblastoma | — | 0.976 |
| 5 | BS_HD4EJYE3 | medulloblastoma | — | 0.976 |
| 6 | BS_GNV89A5P | medulloblastoma | — | 0.975 |
| 7 | BS_M86ECPHK | Embryonal tumors | — | 0.973 |
| 8 | BS_K74PZET7 | medulloblastoma | — | 0.971 |
| 9 | BS_JFB984RG | medulloblastoma | — | 0.968 |
| 10 | BS_DFWFBYSN | medulloblastoma | — | 0.967 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.595 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.498 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.458 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.455 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.326 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.253 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.239 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.235 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.086 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.034 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.026 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.025 | Inavolisib | — uncovered |